Introduction to the generic and trade names of bosutinib/bosutinib

Bosutinib/Bosutinib (Bosutinib) is a targeted drug for patients with chronic myelogenous leukemia (CML) and its accelerated phase or blast phase. It exerts a therapeutic effect by inhibiting the activity of BCR-ABL tyrosine kinase and blocking the proliferation of leukemia cells. Bosutinib, a tyrosine kinase inhibitor for the treatment of leukemia, has been approved globally and is widely used clinically.

Bosutinib's generic name isBosutinib, which is a common identifier for its chemical composition. As a drug's generic name, Bosutinib is widely used by the international medical community and represents the basic component of the drug. Unlike trade names, common names are usually not affected by registered companies and marketing strategies, and are more direct and neutral.

In terms of trade name, Bosutinib is sold under the trade nameBosulif in the United States and many other countries. Bosulif is the commercial name of bosutinib, produced and promoted by the American pharmaceutical company Pfizer. Pfizer, the manufacturer of bosutinib, provides extensive sales channels and support for the drug worldwide. As a trade name, Bosulif has been approved by regulatory agencies in multiple countries and has proven its effectiveness in treating chronic myelogenous leukemia through clinical data.

The launch of Bosutinib/Bosulif provides an effective treatment option for patients with chronic myelogenous leukemia, especially those who are resistant to imatinib or other first-generation tyrosine kinase inhibitors. As a second-generation targeted drug, bosutinib has stronger anti-tumor effects than first-generation drugs and can provide new treatment options for some drug-resistant patients.

Reference materials:https://go.drugbank.com/drugs/DB06616